Biotech Values

[mcbio]

jq, you are the resident BIOD expert so curious if you have any comments on BIOD's recent setback with the recombinant insulin program (#msg-67446709). There's still the analog program, of course, but the setback with the recombinant insulin program effectively makes BIOD a one-trick pony and a true boom or bust stock so I can understand the recent decline.

I'm still holding on to see what happens with the analog program, though. They are still guiding for an announcement at some point this quarter, apparently in terms of whether they'll be moving into the clinic with the analog on their own or with a partner. I think they are trying to improve upon Humalog and ink a deal with LLY in the process (#msg-67473029 ). Curious if you agree with that and have any other comments. If they are indeed trying to improve upon Humalog, doesn't that essentially by default make LLY the only potential partner for an improved Humalog or is it conceivable that someone else could be interested in such a project? (I'm assuming LLY would be the only possible partner in such a scenario, which would presumably be a bad thing for BIOD since they wouldn't have a ton of leverage with only one potential partner.)